Ivacaftor improved measures of CFTR activity (including both chloride conductance monitored by NPD and sweat chloride [16]) and also produced a marked and sustained improvement in pulmonary function in CF patients with G551D-CFTR [15], [16], establishing that mutant CFTR is a valid therapeutic target in CF. Here, CFTR is linked to cystic fibrosis.